Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 601–700 of 1,002
Carlino, F., Diana, A., Ventriglia, A., Piccolo, A., Mocerino, C., Riccardi, F., Bilancia, D., Giotta, F., Antoniol, G., Famiglietti, V., et al. (2022) · Cancers · doi:10.3390/cancers14204981 · Cited by 38
Pfeiler, G., Hlauschek, D., Mayer, E. L., Deutschmann, C., Kacerovsky-Strobl, S., Martín, M., Meisel, J. L., Zdenkowski, N., Loibl, S., Balić, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00126 · Cited by 38
“3,17 Neutropenia is the main reason for dose reduction or early discontinuation of palbociclib treatment.”
BackgroundSelf-citationHenry, N. L., Shah, P. D., Haider, I., Freer, P. E., Jagsi, R., & Sabel, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00088-8 · Cited by 53
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
Gharbi, S., Pelletier, L. A., Espada, A., Gutierrez, J. A., Sanfeliciano, S. G., Rauch, C. T., Ganado, M. P., Baquero, C., Zapatero‐Solana, E., Zhang, A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00494-y · Cited by 38
A Review of the Advancements in Targeted Therapies for Breast Cancer
Jallah, J. K., Dweh, T. J., Anjankar, A. P., & Palma, O. (2023) · Cureus · doi:10.7759/cureus.47847 · Cited by 52
“CDK4-6 inhibitors improve median progression-free survival and delay progression of disease, with ribociclib also showing an improvement in overall survival [18,19].”
BackgroundSchäffler, H., Mergel, F., Pfister, K., Lukac, S., Fink, A., Veselinovic, K., Rack, B. K., Fink, V., Leinert, E., Dimpfl, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216366 · Cited by 40
“…growth factor receptor 2-negative (HER2 − ) breast cancer, recent studies have demonstrated that the addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) resulted in a considerable improvement in progression-free survival (PFS) and overall survival (OS) [5–11].”
BackgroundFulvestrant for the treatment of advanced breast cancer
Blackburn, S. A., Parks, R. M., & Cheung, K. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1473038 · Cited by 39
Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, D., Volovăț, S. R., & Cardoso, F. (2018) · The Breast · doi:10.1016/j.breast.2018.10.001 · Cited by 40
Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population
Clifton, K., Yi, M., Kimmel, J., Litton, J. K., Tripathy, D., & Karuturi, M. S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05181-4 · Cited by 36
Selective oestrogen receptor degraders in breast cancer: a review and perspectives
Gombos, A. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000567 · Cited by 38
Tong, Z., Sathe, A., Ebner, B., Pan, Q., Veltkamp, C., Gschwend, J. E., Holm, P. S., & Nawroth, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1322-9 · Cited by 37
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets
Milioli, H. H., Alexandrou, S., Lim, E., & Caldon, C. E. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0501 · Cited by 41
Sharifi, M. N., Anandan, A., Grogan, P. T., & O'Regan, R. M. (2020) · Cancer · doi:10.1002/cncr.32931 · Cited by 36
Early treatment-related neutropenia predicts response to palbociclib
McAndrew, N. P., Dickson, M. A., Clark, A. S., Troxel, A. B., O’Hara, M. H., Colameco, C., Gallager, M., Gramlich, K., Zafman, K. B., Vaughn, D. J., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0967-7 · Cited by 37
How selective are clinical CDK4/6 inhibitors?
Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 38
Egelston, C. A., Guo, W., Yost, S. E., Lee, J. S., Rose, D. L., Avalos, C., Ye, J., Frankel, P. H., Schmolze, D. D., Waisman, J. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002084 · Cited by 39
The role of CDK4/6 inhibitors in early breast cancer
Gil‐Gil, M., Alba, E., Gavilá, J., de la Haba-Rodríguez, J., Ciruelos, E. M., Tolosa, P., Candini, D., & Llombart‐Cussac, A. (2021) · The Breast · doi:10.1016/j.breast.2021.05.008 · Cited by 37
Han, W., Liu, M., Han, D. G., Toure, A. A., Li, M., Besschetnova, A., Wang, Z., Patalano, S. C., Macoska, J. A., Lam, H., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.039 · Cited by 40
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 37
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
Batra, H. V., Mouabbi, J. A., Ding, Q., Şahin, A. A., & Raso, M. G. (2023) · Cancers · doi:10.3390/cancers15225491 · Cited by 43
“The evidence for this comes from PALOMA-2 phase 3 trials [210] with a Palbociclib and Fulvestrant combination showing an overall better survival benefit.”
BackgroundMethodCDK4/6 inhibitors in lung cancer: current practice and future directions
Lv, S., Yang, J., Lin, J., Huang, X., Zhao, H., Zhao, C., & Yang, L. (2024) · European Respiratory Review · doi:10.1183/16000617.0145-2023 · Cited by 37
Mirza, M. R., Bjørge, L., Marmé, F., Christensen, R. D., Gil-Martín, M., Auranen, A., Ataseven, B., Rubio, M. J., Salutari, V., Luczak, A. A., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.12.003 · Cited by 44
Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Fang, H., Huang, D., Yang, F., & Guan, X. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4612-y · Cited by 36
Brisard, D., Eckerdt, F., Marsh, L. A., Blyth, G. T., Jain, S., Cristofanilli, M., Horiuchi, D., & Platanias, L. C. (2018) · Oncotarget · doi:10.18632/oncotarget.26468 · Cited by 37
Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
Dannehl, D., Volmer, L. L., Weiß, M., Matovina, S., Grischke, E., OBERLECHNER, E., Seller, A., Walter, C. B., Hahn, M., Engler, T., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030382 · Cited by 36
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Koirala, N., Dey, N., Aske, J. C., & De, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126547 · Cited by 36
“CDKi have been approved for use in HR+ MBC based on the impressive PFS data and low toxicity from key trials [65,66,69,74].”
BackgroundMethodClinical impact of body mass index on palbociclib treatment outcomes and effect on exposure
Roncato, R., Peruzzi, E., Gerratana, L., Posocco, B., Nuzzo, S., Montico, M., Orleni, M., Corsetti, S., Bartoletti, M., Gagno, S., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114906 · Cited by 35
Cure in metastatic breast cancer
Westphal, T., Gampenrieder, S. P., Rinnerthaler, G., & Greil, R. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0426-9 · Cited by 37
Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity
Zhou, Y., Li, M., Yu, X., Liu, T., Li, T. X., Zhou, L. Q., Liu, W., Li, W., & Gao, F. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25334 · Cited by 36
Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity
Sittithumcharee, G., Suppramote, O., Vaeteewoottacharn, K., Sirisuksakun, C., Jamnongsong, S., Laphanuwat, P., Suntiparpluacha, M., Matha, A., Chusorn, P., Buraphat, P., et al. (2019) · Hepatology · doi:10.1002/hep.30704 · Cited by 39
“1616 with letrozole significantly increased progression-free survival.(13-15) It is also a promising therapy for several types of other cancer, including glioma,(16) multiple myeloma,(17) and liposarcoma.”
BackgroundQayoom, H., Mehraj, U., Sofi, S., Aisha, S., Almilaibary, A., Alkhanani, M., & Mir, M. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01779-9 · Cited by 35
“Palbociclib, an important CDK4/6 inhibitor Palbociclib, approved by the FDA in first-line or recurrent hormone receptor-positive breast cancer patients was investigated in 2 studies [36, 39].”
BackgroundJardim, D. L. F., Gagliato, D. D. M., Nikanjam, M., Barkauskas, D. A., & Kurzrock, R. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1710052 · Cited by 38
“1), as described in Viechtbauer et al.(16,45) The metaanalysis models were fit using restricted maximum likelihood and the Knapp and Hartung method.”
MethodInfluentialKi67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
Palleschi, M., Maltoni, R., Ravaioli, S., Vagheggini, A., Mannozzi, F., Fanini, F., Pirini, F., Tumedei, M. M., Barzotti, E., Cecconetto, L., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10080573 · Cited by 36
Schettini, F., Giuliano, M., Giudici, F., Conte, B., Placido, P. D., Venturini, S., Rognoni, C., Leo, A. D., Locci, M., Jérusalem, G., et al. (2021) · Cancers · doi:10.3390/cancers13061458 · Cited by 39
Updates in endocrine therapy for metastatic breast cancer
Manohar, P. M., & Davidson, N. E. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0255 · Cited by 40
O'Brien, N. A., Huang, H., McDermott, M. S. J., Madrid, A. M., Luo, T., Ayala, R., Issakhanian, S., Gong, K. W., Lu, M., Zhang, J., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0847 · Cited by 39
Self-citationEser, K., Önder, A. H., Sezer, E., Çil, T., İnal, A., Öztürk, B., Erçolak, V., Duman, B. B., Çelik, H., Köşeci, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09624-y · Cited by 35
Masri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 45
Overview of the therapeutic strategies for ER positive breast cancer
Blakely, B., Shin, S., & Jin, K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115552 · Cited by 34
Yu, Z., He, S., Wang, D., Patel, H., Miller, C. P., Brown, J. L., Hattersley, G., & Saeh, J. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0670 · Cited by 47
“17 CDK4/6 inhibitor recently approved for breast cancer treatment in combination with ER-targeted agents in as early as first line of therapy (45-47), was selected for this study.”
MethodBreast Cancer in Patients 80 Years-Old and Older
Bertolo, A. J., Rosso, C., & Voutsadakis, I. A. (2020) · European Journal of Breast Health · doi:10.5152/ejbh.2020.5659 · Cited by 35
“As options of systemic treatment beyond hormonal therapy and chemotherapy increase in breast cancer and include targeted treatments and immunotherapy, an improved understanding of the disease in the elderly will help with better tailoring of therapies (10, 11).”
BackgroundPascual, J., Gil‐Gil, M., Proszek, P., Zielinski, C. C., Reay, A., Ruíz-Borrego, M., Cutts, R. J., Ciruelos, E., Feber, A., Muñoz-Mateu, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0956 · Cited by 38
Gong, T., Guo, S., Liu, F.-H., Huo, Y.-L., Zhang, M., Shi, Y., Zhou, H., Xu, P., Wang, X., Xu, H.-L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43282-3 · Cited by 36
Li, H., Wu, Y., Zou, H., Koner, S., Plichta, J. K., Tolaney, S. M., Zhang, J., He, Y.-W., Wei, Q., Tang, L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105186 · Cited by 37
“13,14 This fi nding is consistent with previous studies, 1,10 and supports the notion that CDK4/6 inhibitors can effectively target the cell cycle that was enhanced by HER2 signalling, thereby improving the ef fi cacy of ET in HER2-low-pos-itive patients.”
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib
Costa, R., da Costa, R. B., Talamantes, S., Helenowski, I., Peterson, J., Kaplan, J. B., Carneiro, B. A., Giles, F. J., & Gradishar, W. J. (2017) · The Breast · doi:10.1016/j.breast.2017.05.016 · Cited by 37
du Rusquec, P., Palpacuer, C., Campion, L., Patsouris, A., Augereau, P., Gourmelon, C., Robert, M., Dumas, L. E., Folliard, C., Campone, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4623-8 · Cited by 33
Galve-Calvo, E., González-Haba, E., Gostkorzewicz, J., Martínez, I. V., & Pérez-Mitru, A. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s178934 · Cited by 33
“The model considered dose reductions of CDK4/6 inhibitors during treatment, given that during their clinical development, a proportion of patients required dose modifications to alleviate AEs.(8,39) For ribociclib, the dose reductions observed in the MONALEESA-2 trial (data cutoff, January 2, 2017) were applied in eac…”
MethodSante, G. D., Pagé, J., Jiao, X., Nawab, O., Cristofanilli, M., Skordalakes, E., & Pestell, R. G. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615889 · Cited by 34
“tion with aromatase inhibitors [169,171,187], and fulvestrant [167,188,189] for palbociclib, ribociclib, and abemaciclib”
BackgroundRugo, H. S., Finn, R. S., Gelmon, K. A., Joy, A. A., Harbeck, N., Castrellon, A. B., Mukai, H., Walshe, J. M., Mori, A., Gauthier, E., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.009 · Cited by 34
Self-citationKim, D., Wang, C. Y., Hu, R., Lee, J. Y., Luu, T.-T.-T., Park, H.-J., & Lee, S. K. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00720 · Cited by 34
Brandão, M., Maurer, C., Ziegelmann, P. K., Ponde, N. F., Ferreira, A. R., Martel, S., Piccart, M. J., de Azambuja, E., Debiasi, M., & Lambertini, M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000842 · Cited by 34
Management of ER positive metastatic breast cancer
McAndrew, N. P., & Finn, R. S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.005 · Cited by 36
Self-citationEndoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside
Jayaraman, S., Reid, J. M., Hawse, J. R., & Goetz, M. P. (2021) · Endocrinology · doi:10.1210/endocr/bqab191 · Cited by 38
Aicher, T. D., Huis, C. A. V., Hurd, A. R., Skalitzky, D. J., Taylor, C. B., Beleh, O. M., Glick, G. D., Toogood, P. L., Yang, B., Zheng, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00731 · Cited by 33
Lee, J. S., Hackbart, H., Cui, X., & Yuan, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411791 · Cited by 37
“PALOMA-2 [4,5] Palbociclib plus letrozole 666 (2:1) 24.”
Sibaud, V., & Sollena, P. (2023) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2022.11.013 · Cited by 33
Recent Progress in CDK4/6 Inhibitors and PROTACs
Wang, H., Ba, J., Kang, Y., Gong, Z., Liang, T., Zhang, Y., Qi, J., & Wang, J. (2023) · Molecules · doi:10.3390/molecules28248060 · Cited by 33
CDK4/6 blockade in breast cancer: current experience and future perspectives
Zardavas, D., Ponde, N. F., & Tryfonidis, K. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389896 · Cited by 35
“PALOMA-2 (NCT01740427) confirmed the superiority of palbociclib and letrozole for patients with treatment naïve hormone receptor-positive, HER2-negative metastatic BC [46].”
BackgroundRole of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
Giannone, G., Tuninetti, V., Ghisoni, E., Genta, S., Scotto, G., Mittica, G., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092353 · Cited by 35
“It has been approved in combination with an AI for the treatment of HR-positive, HER2-negative advanced BC as a first line ET in postmenopausal women or in combination with fulvestrant for the treatment of HR-positive, HER2-negative advanced or metastatic BC in women with disease progression following endocrine therap…”
MethodThe p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer
Iida, M., Nakamura, M., Tokuda, E., Toyosawa, D., Niwa, T., Ohuchi, N., Ishida, T., & Hayashi, S. (2019) · Oncotarget · doi:10.18632/oncotarget.27127 · Cited by 35
LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein
Cai, Z., Shi, Q., Li, Y., Jin, L., Li, S., Wong, L. L., Wang, J., Jiang, X., Zhu, M., Lin, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi3821 · Cited by 35
Medford, A. J., Dubash, T. D., Juric, D., Spring, L. M., Niemierko, A., Vidula, N., Peppercorn, J. M., Isakoff, S. J., Reeves, B. A., LiCausi, J. A., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0090-5 · Cited by 33
Cyclin-dependent kinase inhibitors for the treatment of lung cancer
Qin, A., Reddy, H. G., Weinberg, F. D., & Kalemkerian, G. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1738385 · Cited by 37
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)
Xu, B., Hu, X., Feng, J., Geng, C., Jin, F., Li, H., Li, M., Li, Q., Liao, N., Liu, D., et al. (2020) · Cancer · doi:10.1002/cncr.32832 · Cited by 34
“5 months) along with acceptable toxicity and improved quality of life.(29) Therefore, combined AI and palbociclib therapy was recommended as the first choice for advanced first-line treatment.”
BackgroundCabel, L., Rosenblum, D., Lerebours, F., Brain, E. G. C., Loirat, D., Bergqvist, M., Cottu, P. H., Donnadieu, A. C., Bethune, A., Kiavué, N., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01334-2 · Cited by 32
Bertho, M., Fraisse, J., Patsouris, A., Cottu, P. H., Arnedos, M., Pérol, D., Jaffré, A., Gonçalvès, A., Lebitasy, M.-P., D’Hondt, V., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987657 · Cited by 34
Predictive biomarkers for systemic therapy of hepatocellular carcinoma
Moldogazieva, N. T., Zavadskiy, S. P., Sologova, S. S., Mokhosoev, I. M., & Terentiev, A. A. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1987217 · Cited by 33
Martín, M., Zielinski, C. C., Ruíz‐Borrego, M., Carrasco, E., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Csőszi, T., Antón, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.006 · Cited by 35
Thill, M., Jackisch, C., Janni, W., Müller, V., Albert, U., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Diel, I., et al. (2019) · Breast Care · doi:10.1159/000500999 · Cited by 36
Self-citationBachelot, T., Cottu, P. H., Chabaud, S., Dalenc, F., Allouache, D., Delaloge, S., Jacquin, J.-P., Grenier, J., Venat‐Bouvet, L., Jegannathen, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02179 · Cited by 34
Primary cilia shape hallmarks of health and aging
Silva, D. F., & Cavadas, C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.04.001 · Cited by 35
Cofano, F., Monticelli, M., Ajello, M., Zenga, F., Marengo, N., Perna, G. D., Altieri, R., Cassoni, P., Bertero, L., Melcarne, A., et al. (2019) · Cancer Control · doi:10.1177/1073274819870549 · Cited by 33
Tan, K., Bryan, J., Segal, B. D., Bellomo, L. P., Nussbaum, N., Tucker, M., Torres, A. Z., Bennette, C., Capra, W. B., Curtis, M. D., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2351 · Cited by 32
Denkert, C., Rachakonda, S., Karn, T., Weber, K. E., Martin, M., Marmé, F., Untch, M., Bonnefoi, H. R., Kim, S., Seiler, S., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.002 · Cited by 34
Self-citationCell Cycle Regulation in Treatment of Breast Cancer
Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 37
New developments in brain metastases
Berghoff, A. S., & Preusser, M. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418785502 · Cited by 31
Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma
Teh, J. L. F., Purwin, T. J., Han, A., Chua, V. Y. L., Patel, P. S., Baqai, U., Liao, C., Bechtel, N., Sato, T., Davies, M. A., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1016 · Cited by 34
“Three selective CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are currently FDA approved for patients with estrogen receptor–positive (ERþ) breast cancer in combination with ER antagonists (11, 12).”
BackgroundRatoša, I., Oražem, M., Scoccimarro, E., Steinacher, M., Dominici, L., Aquilano, M., Cerbai, C., Desideri, I., Ribnikar, D., Marinko, T., et al. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.05.013 · Cited by 31
Finn, R. S., Cristofanilli, M., Ettl, J., Gelmon, K. A., Colleoni, M. A., Giorgetti, C., Gauthier, E. R., Liu, Y., Lu, D. R., Zhang, Z., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05782-4 · Cited by 33
Self-citationDavid, S., Ho, G., Day, D., Harris, M., Tan, J., Goel, S., Hanna, G. G., Srivastava, R., Kruss, G., McDowell, L. J., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100939 · Cited by 31
“[1] RS Finn , M Martin , HS Rugo , S Jones , S-A Im , K Gelmon , et al.”
BackgroundBrighi, N., Conteduca, V., Lolli, C., Gurioli, G., Schepisi, G., Palleschi, M., Mariotti, M., Casadei, C., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103199 · Cited by 33
Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
Mycock, K., Zhan, L., Taylor‐Stokes, G., Milligan, G., & Mitra, D. (2021) · Current Oncology · doi:10.3390/curroncol28010066 · Cited by 31
“The palbociclib dose was reduced in 36.0% of patients treated with palbociclib + letrozole in PALOMA-2 [17] and in 33.9% of patients treated with palbociclib + fulvestrant in PALOMA-3 [18].”
BackgroundInfluentialBeachler, D. C., de Luise, C., Jamal‐Allial, A., Yin, R., Taylor, D. H., Suzuki, A., Lewis, J. H., Freston, J. W., & Lanes, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-07790-z · Cited by 34
“Randomized-controlled trials (PALOMA 2/3) [2, 3] demonstrated that palbociclib prolonged progressionfree survival by 5 to 10 months when used in combination with letrozole or fulvestrant compared to endocrine monotherapy.”
BackgroundKristensen, K. B., Thomsen, I. M. N., Berg, T., Kodahl, A. R., & Jensen, A. B. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06215-6 · Cited by 31
“Palbociclib in 2016 based on the PALOMA-trials [8, 9], abemaciclib in 2018 following the MONARCH-trials [10] and ribociclib in 2017 based on the MONALEESA trials.”
MethodIwata, H., Umeyama, Y., Liu, Y., Zhang, Z., Schnell, P., Mori, Y., Fletcher, O., Marshall, J.-C. A., Johnson, J. G., Wood, L. S., et al. (2021) · The Oncologist · doi:10.1002/onco.13811 · Cited by 35
“Both studies were conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki [4, 5].”
BackgroundMethodSelf-citationGelmon, K. A., Walshe, J. M., Mahtani, R. L., Joy, A. A., Karuturi, M. S., Neven, P., Lu, D. R., Kim, S., Schnell, P., Bananis, E., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.07.017 · Cited by 32
Self-citationBrufsky, A., Liu, X., Li, B. C., McRoy, L., & Layman, R. M. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00826-1 · Cited by 34
Kahán, Z., Gil‐Gil, M., Ruíz‐Borrego, M., Carrasco, E., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Antón, A., Casas, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.004 · Cited by 33
Zhu, L., Wang, M., Luo, X., Li, H., Han, S., Du, Q., & Zhai, Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5110 · Cited by 32
“For endocrine-sensitive population, clinical trials (palbociclib: PALOMA-2; ribociclib: MONALEESA-2, MONALEESA-3, MONALEESA-7; abemacic l ib : MONARCH-3) found that palbociclib, ribociclib and abemaciclib plus letrozole or fulvestrant all obtained significantly longer PFS than endocrine therapy alone in clinical trial…”
BackgroundBardia, A., Cortés, J., Hurvitz, S. A., Delaloge, S., Iwata, H., Shao, Z., Kanagavel, D., Cohen, P., Liu, Q., Cartot‐Cotton, S., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083956 · Cited by 32
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer
Watson, N. W., Wander, S. A., Shatzel, J. J., & Al-Samkari, H. T. (2022) · Cancer · doi:10.1002/cncr.34367 · Cited by 33
Engler, T., Fasching, P. A., Lüftner, D., Hartkopf, A. D., Müller, V., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1880-0087 · Cited by 31
SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors
Huang, Z., Li, X., Tang, B., Li, H., Zhang, J., Sun, R., Ma, J., Pan, Y., Yan, B., Zhou, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0264 · Cited by 32
HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
Jerzak, K. J., Bouganim, N., Brezden‐Masley, C., Edwards, S. J., Gelmon, K. A., Henning, J., Hilton, J. F., & Sehdev, S. R. (2023) · Current Oncology · doi:10.3390/curroncol30060411 · Cited by 36
“The CDK4/6i were studied in combination with an AI for first-line use in HR+/HER2– patients with postmenopausal advanced breast cancer in PALOMA-2 (palbociclib + letro-Curr zole) [10,11], MONALEESA-2 (ribociclib + letrozole) [12], and MONARCH-3 (abemaciclib + nonsteroidal AI) [13].”
Self-citationGao, F., Wu, Y., Wang, R., Yao, Y., Liu, Y., Fan, L., Xu, J., Zhang, J., Han, X., & Guan, X. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.012 · Cited by 32
“The PALOMA-2 trial suggested the synergistic application of palboci-clib, acellcycleinhibitor,alongside endocrine therapy, contributing to a longer progression-free survival (PFS) for patients with ER-positive breast cancer 22 .”
Preclinical and clinical development of palbociclib and future perspectives
de Dueñas, E. M., Gavilá-Gregori, J., Olmos-Antón, S., Santaballa, A., Lluch-Hernández, A., Domínguez, E. E., Rivero-Silva, M., & Llombart‐Cussac, A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1850-3 · Cited by 36
“Following the results of the PALOMA-2 trial, letrozole with palbociclib is currently a preferred option in the first-line setting [27].”
BackgroundResultLi, J., Wang, Z., & Shao, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2095 · Cited by 31
CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard
Wolff, A. C. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611926 · Cited by 34
Breast Cancer Research and Treatment
(2013) · Breast Cancer Research and Treatment · doi:10.1007/10549.1573-7217 · Cited by 31
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Johnston, S. R. D., Emde, A., Barrios, C. H., Srock, S., Neven, P., Martin, M., Cameron, D., Janni, W., & Gnant, M. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad045 · Cited by 33
Self-citation
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.